Compensation of the Executive Committee for 2025
The following table discloses the actual compensation paid to the members of the Executive Committee in detail for financial year 2025 while performing services for medmix.
2025 | ||||||||||||||
Cash compensation | Deferred compensation based on future performance | |||||||||||||
thousands of CHF | Base salary | Bonus2) | Other3) | Pension and social security contributions4) | Total cash-based compen- sation | Estimated value of share-based grant under the Perfor- mance Share Plan (PSP)5) | Total (incl. conditional share-based grant) | |||||||
thereof highest single compensation R. Willi, CEO | 600 | 580 | 30 | 304 | 1’513 | 587 | 2’100 | |||||||
Total Executive Committee1) | 1’998 | 1’492 | 41 | 927 | 4’457 | 997 | 5’455 | |||||||
1)The total Executive Committee compensation for 2025 includes the compensation of René Willi, CEO; Jennifer Dean, CFO; Itee Satpathy, former CHRO on garden leave until 31 August 2025; Jasper Den Ouden, Chief HR & Sustainability Officer since March 2025; Xavier Schops, Chief Legal Officer; Girts Cimermans, former CEO on garden leave until 30 April 2025.
2)Expected bonus for the performance year 2025 to be paid out in the following year (accrual principle).
3)Other includes child- , schooling- , insurance- and car allowances, and tax services.
4)Includes the employer contribution to social security.
5)Represents the full fair value of the PSUs granted under PSP 2025. Grant price was CHF 11.48 (three-month volume weighted average share price) and the fair value was CHF 11.23 based on a third-party calculation.
2024 | ||||||||||||||
Cash compensation | Deferred compensation based on future performance | |||||||||||||
thousands of CHF | Base salary | Bonus2) | Other3) | Pension and social security contributions4) | Total cash-based compen- sation | Estimated value of share-based grant under the Perfor- mance Share Plan (PSP) / Restricted Share Units (RSU)5) | Total (incl. conditional share-based grant) | |||||||
thereof highest single compensation R. Willi, CEO | 350 | 273 | 169 | 209 | 1’001 | 2’553 | 3’554 | |||||||
Total Executive Committee1) | 1’950 | 1’212 | 448 | 950 | 4’560 | 2’940 | 7’499 | |||||||
1)The total Executive Committee compensation for 2024 includes the compensation of René Willi, CEO since June 2024; Jennifer Dean, CFO; Itee Satpathy, Chief Human Resources Officer; Xavier Schops, Chief Legal Officer; Girts Cimermans, former CEO on garden leave until 30 April 2025.
2)Expected bonus for the performance year 2024 to be paid out in the following year (accrual principle).
3)Other includes child- , schooling- , insurance- and car allowances, and tax services. For 2024, this category also includes (i) a one-time payment to J. Dean for the additional work in the interim period after Girts Cimermans stepped down and before René Willi assumed his position as CEO.
4)Includes the employer contribution to social security.
5)Represents the full fair value of the PSUs granted under PSP 2024. Grant price was CHF 16.40 (three-month volume weighted average share price) and the fair value was CHF 15.11 based on a third-party calculation. Inlcuded is also an RSU award of CHF 2 million (full fair value at grant) to R. Willi to compensate for forfeited Long Term Incentive at the previous employer as a result of joining medmix.
The total compensation of kCHF 5'455 awarded to the members of the Executive Committee for the financial year 2025 is within the maximum aggregate compensation amount of kCHF 8'500 that was approved by the shareholders at the 2024 AGM for financial year 2025.
No severance payments to members of the Executive Committee were made during the reporting year or the prior year. As of December 31, 2025 and 2024, respectively, there were no outstanding loans or credits granted to the members of the Executive Committee or related parties. In 2025 and 2024, respectively, no compensation, loans or credits were granted to former members of the Executive Committee or related parties.